The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
Official Title: An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
Study ID: NCT04400383
Brief Summary: This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
Detailed Description: This study is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors. The study is composed of two stages: stage I is single treatment and stage II is combo treatment.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Anhui Provincial Hospital, Hefei, Anhui, China
Beijing Cancer Hospital, Beijing, Beijing, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Xiangya Hospital Central South University, Changsha, Hunan, China
Huaihua Second People's Hospital, Huaihua, Hunan, China
Linyi Cancer Hospital, Linyi, Shandong, China
Zhongshan Hospital, Zhongshan University, Shanghai, Shanghai, China
Shanghai East Hospital, Shanghai, Shanghai, China
The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
Name: Jin Li
Affiliation: Shanghai East Hospital
Role: PRINCIPAL_INVESTIGATOR